Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1993 1
1996 3
1999 2
2003 2
2004 5
2005 9
2006 8
2007 5
2008 9
2009 13
2010 23
2011 18
2012 24
2013 23
2014 29
2015 31
2016 50
2017 34
2018 48
2019 74
2020 80
2021 83
2022 108
2023 111
2024 95
2025 121
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

918 results

Results by year

Filters applied: . Clear all
Page 1
Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis.
Park MD, Le Berichel J, Hamon P, Wilk CM, Belabed M, Yatim N, Saffon A, Boumelha J, Falcomatà C, Tepper A, Hegde S, Mattiuz R, Soong BY, LaMarche NM, Rentzeperis F, Troncoso L, Halasz L, Hennequin C, Chin T, Chen EP, Reid AM, Su M, Cahn AR, Koekkoek LL, Venturini N, Wood-Isenberg S, D'souza D, Chen R, Dawson T, Nie K, Chen Z, Kim-Schulze S, Casanova-Acebes M, Swirski FK, Downward J, Vabret N, Brown BD, Marron TU, Merad M. Park MD, et al. Among authors: nie k. Science. 2024 Oct 25;386(6720):eadn0327. doi: 10.1126/science.adn0327. Epub 2024 Oct 25. Science. 2024. PMID: 39236155 Free PMC article.
Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, Crump T, Walsh LA, Fiset PO, Sepesi B, Forde PM, Cascone T, Provencio M, Spicer JD. Sorin M, et al. Among authors: nie k. JAMA Oncol. 2024 May 1;10(5):621-633. doi: 10.1001/jamaoncol.2024.0057. JAMA Oncol. 2024. PMID: 38512301 Free PMC article.
Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours.
Hegde S, Giotti B, Soong BY, Halasz L, Le Berichel J, Schaefer MM, Kloeckner B, Mattiuz R, Park MD, Magen A, Marks A, Belabed M, Hamon P, Chin T, Troncoso L, Lee JJ, Fan K, Ahimovic D, Bale MJ, Nie K, Chung G, D'souza D, Angeliadis K, Kim-Schulze S, Flores RM, Kaufman AJ, Ginhoux F, Buenrostro JD, Josefowicz SZ, Tsankov AM, Marron TU, Ma S, Brown BD, Merad M. Hegde S, et al. Among authors: nie k. Nature. 2025 Oct;646(8087):1214-1222. doi: 10.1038/s41586-025-09493-y. Epub 2025 Sep 10. Nature. 2025. PMID: 40931076
Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma.
Molina-Sánchez P, Ruiz de Galarreta M, Yao MA, Lindblad KE, Bresnahan E, Bitterman E, Martin TC, Rubenstein T, Nie K, Golas J, Choudhary S, Bárcena-Varela M, Elmas A, Miguela V, Ding Y, Kan Z, Grinspan LT, Huang KL, Parsons RE, Shields DJ, Rollins RA, Lujambio A. Molina-Sánchez P, et al. Among authors: nie k. Gastroenterology. 2020 Dec;159(6):2203-2220.e14. doi: 10.1053/j.gastro.2020.08.015. Epub 2020 Aug 16. Gastroenterology. 2020. PMID: 32814112 Free PMC article.
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, Walter RB, Pettit K, Savona MR, Shah MV, Kremyanskaya M, Baer MR, Foran JM, Schiller G, Adès L, Heiblig M, Berthon C, Peterlin P, Rodríguez-Arbolí E, Salamero O, Patnaik MM, Papayannidis C, Grembecka J, Cierpicki T, Clegg B, Ray J, Linhares BM, Nie K, Mitra A, Ahsan JM, Tabachri M, Soifer HS, Corum D, Leoni M, Dale S, Fathi AT. Wang ES, et al. Among authors: nie k. Lancet Oncol. 2024 Oct;25(10):1310-1324. doi: 10.1016/S1470-2045(24)00386-3. Lancet Oncol. 2024. PMID: 39362248 Clinical Trial.
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: nie k. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
918 results